Idacio®

(adalimumab)

For Republic of Ireland healthcare professionals only. This content contains promotional and brand information.
 
Scroll down for IDACIO prescribing information and further product details. For adverse event reporting see bottom of webpage.

IDACIO 40 mg solution for injection in pre-filled pen.
IDACIO 40 mg solution for injection in pre-filled syringe.

For the Republic of Ireland, the SmPC and Patient Leaflets are located on the Medicines.ie | Reliable & Accurate Online Medicines Information (medicines.ie)

Note: by clicking the link you will leave the Fresenius Kabi Ireland website and be directed to the electronic medicines compendium website.
Filename
Idacio® Prescribing Information.pdf
Size
1 MB
Format
pdf
Idacio® Prescribing Information.pdf

Details

The Idacio 40mg solution for injection in a pre-filled pen and pre-filled syringe are indicated for use in the following conditions. Please consult the SmPC before prescribing. Idacio treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of conditions for which Idacio is indicated.
  • Rheumatoid arthritis
  • Juvenile idiopathic arthritis
  • Axial spondyloarthritis
  • Psoriatic arthritis
  • Psoriasis
  • Paediatric plaque psoriasis
  • Hidradenitis suppurativa (HS)
  • Crohn's disease
  • Paediatric Crohn's disease
  • Ulcerative colitis
  • Paediatric ulcerative colitis
  • Uveitis
  • Paediatric Uveitis

Item codeDescriptionPresentationCase Qty
F0910202Idacio 40mgPre filled syringe 0.8ml2
F0910203Idacio 40mgPre filled pen 0.8ml2


Adverse events should be reported.
Reporting forms and information can be found at:
www.hpra.ie/homepage/about-us/report-an-issue
Adverse events should also be reported to Fresenius Kabi Limited, Cestrian Court, Eastgate Way, Manor Park, Runcorn, Cheshire, WA7 1NT Tel +44 (0)1928 533 533.

Job code: IE-IDA-2400026

Date of preparation: December 2024

This is intended for healthcare professionals in the Republic of Ireland only and contains information about Fresenius Kabi medicines. By accessing this information you are confirming you are a healthcare professional in the Republic of Ireland.

If you are a healthcare professional based in Northern Ireland please access the Fresenius Kabi UK site here for more information. www.fresenius-kabi.com/gb

If you are not a healthcare professional, please return to the Fresenius Kabi Ireland homepage where you can find more information for the public and for patients using Fresenius Kabi medicines or products.

IE-NP-2400056 November 2024